Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 214

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis

Open access
Atisha‐Fregoso, Yemil, Malkiel, Susan, Harris, Kristina M., Byron, Margie, Ding, Linna, Kanaparthi, Sai, Barry, William T., Gao, Wendy, Ryker, Kristin, Tosta, Patti, Askanase, Anca D., Boackle, Susan A., Chatham, W. Winn, Kamen, Diane L., Karp, David R., Kirou, Kyriakos A., Sam Lim, S., Marder, Bradley, McMahon, Maureen, Parikh, Samir V., Pendergraft, William F., Podoll, Amber S., Saxena, Amit, Wofsy, David, Diamond, Betty, Smilek, Dawn E., Aranow, Cynthia, Dall’Era, Maria · 2021 · Arthritis & Rheumatology

Abstract

Objective: To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of refractory lupus nephritis (LN). Methods: In a multicenter, randomized, open‐label clinical trial, 43 patients with recurrent or refractory LN were treated with rituximab, cyclophosphamide (CYC), and glucocorticoids followed by weekly belimumab infusions until week 48 (RCB group), or treated with rituximab and CYC but no belimumab infusions (RC group). Patients were followed up until week 96. Percentages of total and autoreactive B cell subsets in the patients’ peripheral blood were analyzed by flow cytometry. Results: Treatment with belimumab did not increase the incidence of adverse events in patients with refractory LN. At week 48, a complete or partial renal response occurred in 11 (52%) of 21 patients receiving belimumab, compared to 9 (41%) of 22 patients in the RC group who did not receive belimumab (P = 0.452). Lack of improvement in or worsening of LN was the major reason for treatment failure. B cell depletion occurred in both groups, but the percentage of B cells remained lower in those receiving belimumab (geometric mean number of B cells at week 60, 53 cells/μl in the RCB group versus 11 cells/μl in the RC group; P = 0.0012). Percentages of total and autoreactive transitional B cells increased from baseline to week 48 in both groups. However, percentages of total and autoreactive naive B cells decreased from baseline to week 48 in the belimumab group compared to the no belimumab RC group (P = 0.0349), a finding that is consistent with the observed impaired maturation of naive B cells and enhanced censoring of autoreactive B cells. Conclusion: The addition of belimumab to a treatment regimen with rituximab and CYC was safe in patients with refractory LN. This regimen diminished maturation of transitional to naive B cells during B cell reconstitution, and enhanced the negative selection of autoreactive B cells. Clinical efficacy was not improved with rituximab and CYC in combination with belimumab when compared to a therapeutic strategy of B cell depletion alone in patients with LN.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.41466

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 214

Metadata

Authors
Atisha‐Fregoso, Y., Malkiel, S., Harris, K. M., Byron, M., Ding, L., Kanaparthi, S., Barry, W. T., Gao, W., Ryker, K., Tosta, P., Askanase, A. D., Boackle, S. A., Chatham, W. W., Kamen, D. L., Karp, D. R., Kirou, K. A., Sam Lim, S., Marder, B., McMahon, M., Parikh, S. V., Pendergraft, W. F., Podoll, A. S., Saxena, A., Wofsy, D., Diamond, B., Smilek, D. E., Aranow, C., & Dall’Era, M.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2020-12
Volume
73
Issue
1
Pages
121-131
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W3047551100
Cited by
214
References
1
FWCI
18.43
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.